Brainsway treatment sharply reduces smoking addiction
84% of smokers in a trial of the company's Deep TMS device stopped smoking.
The 115 participants in the study were divided into three groups: one group received a placebo, the second group received infrequent treatments, and the third group received frequent treatments. Half of the participants in each group first received a stimulant to temporarily increase the desire to smoke. 78 patients completed the study: 32 who received frequent treatments, 14 who received infrequent treatments and 32 who received the placebo. The infrequent treatments were terminated when the interim results showed that they were ineffective in stopping smoking.
Earlier this month, the US Food and Drug Administration (FDA) and Health Canada approved the Deep TMS device for the treatment of depression in patients who do not respond to drugs.
Published by Globes [online], Israel business news - www.globes-online.com - on January 24, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options